Vima Raises $100 Million in Series A to Advance Parkinson's Disease Treatment. Their selective muscarinic agonist is currently in mid-stage development. This medicine is intended for the treatment of movement disorders such as Parkinson's disease and dystonia. The funding will enable further development of this potential drug. Vima focuses on advanced stages of clinical trials. The project represents an investment in new possibilities of pharmacotherapy.